Until Labs Secures $58M to Advance Organ Cryopreservation Technology

Until Labs, a company pioneering reversible cryopreservation of biological systems, has secured $58 million in Series A funding led by Founders Fund, with participation from Lux Capital and Field Ventures. The funding will enable the company to expand its multidisciplinary team of experts across chemistry, biology, and engineering disciplines as it works to revolutionize organ preservation and transplantation.

The company's primary focus centers on developing organ-scale reversible cryopreservation technology that would preserve donor organs at temperatures enabling indefinite storage, then rewarm them for successful transplantation. This breakthrough addresses one of the most pressing challenges in organ transplantation, where donor organs remain viable for extremely limited timeframes after procurement. Hearts, lungs, and livers currently remain viable for only 4-12 hours, while kidneys can last 24-36 hours.

These severe time constraints create significant logistical barriers in the transplant system. Patients must live within two hours of their transplant center to receive organs, and thousands of potentially life-saving organs are lost each year due to logistical delays or the inability to find a timely match. Until Labs' technology aims to eliminate these constraints, ensuring that every donated organ with the potential to save a life can be successfully utilized.

The company's research trajectory has evolved from initial work with slices of neural tissue to current efforts focused on preclinical model organs. A diverse team of specialists in perfusion, molecular biology, hardware engineering, and physics is developing innovative methods to maximize organ quality following cryopreservation. This collaborative approach combines expertise across multiple scientific disciplines to tackle the complex challenges of biological preservation.

Beyond immediate organ preservation applications, Until Labs maintains an ambitious long-term vision to build the medical infrastructure necessary to pause biological time. The company views its organ-scale cryopreservation work as a foundational step toward developing whole-body medical hibernation technology. This ultimate goal represents a paradigm shift in medical capabilities, potentially enabling new treatments and interventions that require extended biological preservation.

The substantial Series A funding reflects investor confidence in Until Labs' approach to solving critical healthcare challenges through advanced cryopreservation technology, positioning the company at the forefront of a potentially transformative field in medicine.

Click here for the original news story.